Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Laser vaporization is less invasive than conization for cervical intraepithelial neoplasia (CIN). The outcome of laser vaporization for CIN is empirically known to depend on the colposcopic findings, especially localization of the lesion. In this study, we sought to identify factors involved in the outcome of laser vaporization. MATERIALS AND METHODS: We retrospectively investigated 290 cases of CIN (CIN2, n = 180; CIN3, n = 110) treated with laser evaporation at Nishikawa Women's Health Clinic between 2018 and 2021. All treatments were performed using a carbon dioxide laser under either colposcopic vision (n = 172) or direct vision using a vaginal speculum (n = 118). Risk factors were statistically examined for cure rate after treatment. RESULTS: Multivariate analysis using a logistic regression model identified independent factors affecting the success of treatment to be high-risk human papillomavirus infection status preoperatively, CIN grade, presence of CIN lesions at the periphery of the cervix, and the surgical method used. Colposcopy-guided laser vaporization reduced the risk of treatment failure by 84% (odds ratio 0.16, 95% confidence interval 0.06-0.46; p = 0.001) compared with direct vision using a vaginal speculum. For lesions at the periphery of the cervix, most of the treatment failures were in the group that was not guided by colposcopy (p = 0.031). CONCLUSION: The presence of a peripheral CIN lesion was suggested to be a risk factor for treatment failure. Laser vaporization under colposcopic vision is recommended for treatment of peripheral CIN lesions.

DOI： 10.1016/j.tjog.2024.06.012

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Vaginal trachelectomy, which involves resecting the cervix and its parametrium, is a fertility-sparing option for the treatment of early-stage cervical cancer. Although no consensus has been reached on whether simple or radical trachelectomy is preferable, the vaginal approach is typically avoided for tumors larger than 2 cm due to concerns about recurrence. However, some evidence suggests that fertility preservation may still be viable for select patients with larger tumors. This case report describes a woman with bulky cervical cancer who wished to preserve her fertility. After undergoing neoadjuvant chemotherapy (NAC) and vaginal radical trachelectomy (VRT), she achieved a favorable oncological and perinatal outcome, successfully giving birth to a near-full-term baby. The report outlines the patient's management before, during, and after the procedure, including perinatal care. While careful selection of candidates is crucial, accumulating case reports and future trials are expected to shed more light on this treatment approach.

DOI： 10.7759/cureus.71626

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Neoantigens arising from somatic mutations are tumor specific and induce antitumor host T cell responses. However, their sequences are individual specific and need to be identified for each patient for therapeutic applications. Here, we present a proteogenomic approach for neoantigen identification, named Neoantigen Selection using a Surrogate Immunopeptidome (NESSIE). This approach uses an autologous wild-type immunopeptidome as a surrogate for the tumor immunopeptidome and allows human leukocyte antigen (HLA)-agnostic identification of both HLA class I (HLA-I) and HLA class II (HLA-II) neoantigens. We demonstrate the direct identification of highly immunogenic HLA-I and HLA-II neoantigens using NESSIE in patients with colorectal cancer and endometrial cancer. Fresh or frozen tumor samples are not required for analysis, making it applicable to many patients in clinical settings. We also demonstrate tumor prevention by vaccination with selected neoantigens in a preclinical mouse model. This approach may benefit personalized T cell-mediated immunotherapies.

DOI： 10.1126/sciadv.ado6491

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

This study examined the risk of intrauterine infection associated with radical trachelectomy (RT) in early-stage cervical cancer patients. This procedure preserves fertility but is linked to increased risk of intrauterine infection due to cervical defects during pregnancy. DNA was extracted from the formalin-fixed paraffin-embedded (FFPE) placental specimens of 23 pregnant post-RT patients and 16S rRNA gene sequencing was used for bacterial identification. The prevalence of Lactobacillus crispatus and Burkholderia stabilis was significantly higher in the non-chorioamnionitis group. In contrast, alpha diversity analysis using the PD index showed significantly higher diversity in the chorioamnionitis group (P = 0.04). The demonstrated relationship between chorioamnionitis and microbial diversity affirms the importance of controlling the genital bacterial flora in pregnancies following RT.

DOI： 10.1002/2211-5463.13892

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The application of deep learning algorithms to predict the molecular profiles of various cancers from digital images of hematoxylin and eosin (H&E)-stained slides has been reported in recent years, mainly for gastric and colon cancers. In this study, we investigated the potential use of H&E-stained endometrial cancer slide images to predict the associated mismatch repair (MMR) status. H&E-stained slide images were collected from 127 cases of the primary lesion of endometrial cancer. After digitization using a Nanozoomer virtual slide scanner (Hamamatsu Photonics), we segmented the scanned images into 5397 tiles of 512 × 512 pixels. The MMR proteins (PMS2, MSH6) were immunohistochemically stained, classified into MMR proficient/deficient, and annotated for each case and tile. We trained several neural networks, including convolutional and attention-based networks, using tiles annotated with the MMR status. Among the tested networks, ResNet50 exhibited the highest area under the receiver operating characteristic curve (AUROC) of 0.91 for predicting the MMR status. The constructed prediction algorithm may be applicable to other molecular profiles and useful for pre-screening before implementing other, more costly genetic profiling tests.

DOI： 10.3390/cancers16101810

PubMed

researchmap

Language：English  

DOI： 10.1038/s10038-024-01241-w

PubMed

researchmap

Language：English  

A 31-year-old female sought termination of pregnancy due to a fetal body stalk anomaly diagnosed at 18 weeks of gestation. Despite an anterior placenta previa, successful vaginal delivery occurred. However, placental adhesion over a previous cesarean scar occurred, and part of the placenta could not be removed. Immediate postpartum bleeding prompted imaging studies, revealing extravasation from adherent placental remnants. Uterine artery embolization (UAE) provided initial hemostasis, but recurrent bleeding necessitated re-embolization. Although conservative treatment was initially pursued, significant hematuria prompted reevaluation, revealing extensive uterine wall and bladder penetration. Surgical intervention with total hysterectomy and partial bladder resection was performed, leading to the successful recovery of bladder function following surgical repair. While this case achieved a positive outcome, there is a potential for permanent urinary dysfunction if lesions are more extensive. While achieving a conservative cure is ideal, it is essential to assess the timing for opting for surgical intervention.

DOI： 10.7759/cureus.55651

PubMed

researchmap

Language：English   Publisher：(一社)日本癌学会  

DOI： 10.1038/s10038-024-01233-w

PubMed

Ichushi

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND/AIM: Clear cell carcinoma is a prevalent histological type of ovarian cancer in East Asia, particularly in Japan, known for its resistance to chemotherapeutic agents and poor prognosis. ARID1A gene mutations, commonly found in ovarian clear cell carcinoma (OCCC), contribute to its pathogenesis. Recent data revealed that the ARID1A mutation is related to better outcomes of cancer immunotherapy. Thus, this study aimed to investigate the immunotherapy treatment susceptibility of OCCC bearing ARID1A mutations. MATERIALS AND METHODS: Expression of ARID1A was analyzed using western blotting in ovarian cancer cell lines. OCCC cell lines JHOC-9 and RMG-V were engineered to overexpress NY-ESO-1, HLA-A*02:01, and ARID1A. Sensitivity to chemotherapy and T cell receptor-transduced T (TCR-T) cells specific for NY-ESO-1 was assessed in ARID1A-restored cells compared to ARID1A-deficient wild-type cells. RESULTS: JHOC-9 cells and RMG-V cells showed no expression of ARID1A protein. Overexpression of ARID1A in JHOC-9 and RMG-V cells did not impact sensitivity to gemcitabine. While ARID1A overexpression decreased sensitivity to cisplatin in RMG-V cells, it had no such effect in JHOC-9 cells. ARID1A overexpression reduced the reactivity of NY-ESO-1-specific TCR-T cells, as observed by the IFNγ ESLIPOT assay. CONCLUSION: Cancer immunotherapy is an effective approach to target ARID1A-deficient clear cell carcinoma of the ovary.

DOI： 10.21873/cgp.20460

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Early diagnosis is essential for the safer perinatal management of placenta accreta spectrum (PAS). We used transcriptome analysis to investigate diagnostic maternal serum biomarkers and the mechanisms of PAS development. We analyzed eight formalin-fixed paraffin-embedded placental specimens from two placenta increta and three placenta percreta cases who underwent cesarean hysterectomy at Sapporo Medical University Hospital between 2013 and 2019. Invaded placental regions were isolated from the uterine myometrium and RNA was extracted. The transcriptome difference between normal placenta and PAS was analyzed by microarray analysis. The PAS group showed markedly decreased expression of placenta-specific genes such as LGALS13 and the pregnancy-specific beta-1-glycoprotein (PSG) family. Term enrichment analysis revealed changes in genes related to cellular protein catabolic process, female pregnancy, autophagy, and metabolism of lipids. From the highly dysregulated genes in the PAS group, we investigated the expression of PSG family members, which are secreted into the intervillous space and can be detected in maternal serum from the early stage of pregnancy. The gene expression level of PSG6 in particular was progressively decreased from placenta increta to percreta. The PSG family, especially PSG6, is a potential biomarker for PAS diagnosis.

DOI： 10.1007/s00795-023-00371-y

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: This study aims to evaluate the endocrine differences among polycystic ovary syndrome (PCOS) phenotypes in Japanese women. METHODS: 118 Japanese women that we diagnosed with PCOS agreed to be included in the study. The study group was classified into the following four phenotypes: A) hyperandrogenism (HA); ovulatory disorder (OvD) and polycystic ovary morphology (PCOM); B) HA and OvD; C) HA and PCOM; and D) OvD and PCOM. We also recruited 66 healthy Japanese women to the study as control participants. Age, body mass index, androgens, luteinizing hormone, follicle-stimulating hormone, and insulin resistance index were evaluated and compared. RESULTS: The proportions of phenotypes A, B, C, and D were 57/120 (47.5%), 4/120 (3.3%), 13/120 (10.8%), and 46/120 (38.3%), respectively. The proportion of phenotype B was too small; therefore, phenotypes A and B were grouped as classical PCOS for intergroup comparisons. The luteinizing hormone/follicle-stimulating hormone ratio in the classical PCOS group was higher than that in the phenotype D group (P < 0.001). Androgen concentrations in the phenotype D group were significantly lower than those in the other groups (P < 0.01). Phenotype D was more common in lean women with PCOS. The surrogate marker of insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR)) was not different irrespective of PCOS and its phenotypes. CONCLUSION: Except for androgens, endocrine differences by PCOS phenotype are not evident, suggesting that diversity among patients with PCOS is relatively low in Japanese women.

DOI： 10.1016/j.jogc.2023.102217

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Constitutional complex chromosomal rearrangements (CCRs) are rare cytogenetic aberrations arising in the germline via an unknown mechanism. Here we analyzed the breakpoint junctions of microscopically three-way or more complex translocations using comprehensive genomic and epigenomic analyses. All of these translocation junctions showed submicroscopic genomic complexity reminiscent of chromothripsis. The breakpoints were clustered within small genomic domains with junctions showing microhomology or microinsertions. Notably, all of the de novo cases were of paternal origin. The breakpoint distributions corresponded specifically to the ATAC-seq (assay for transposase-accessible chromatin with sequencing) read data peak of mature sperm and not to other chromatin markers or tissues. We propose that DNA breaks in CCRs may develop in an accessible region of densely packaged chromatin during post-meiotic spermiogenesis.

DOI： 10.1007/s00439-023-02591-9

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

AIM: Obstetrical guidelines were established in Japan in 2008, and obstetrical diagnoses and treatments were subsequently standardized nationally. We examined changes in the preterm birth rate (PTBR) and extremely preterm birth rate (EPTBR) following the introduction of such guidelines. METHODS: Information on 50 706 432 live births in Japan between 1979 and 2021, including Japanese reproductive medicine, the childbearing age of pregnant women, and the employment status of reproductive-age women between 2007 and 2020, were obtained from the Japanese government and academic societies. Regression analysis was used to compare chronological changes nationally and those of eight Japanese regions. Regional and national average PTBRs and EPTBRs from 2007 to 2020 were compared by using a repeated measures analysis of variance. RESULTS: From 1979 to 2007, PTBRs and EPTBRs in Japan increased significantly. However, from 2008, the national PTBR and EPTBR decreased until 2020 (p < 0.001) and 2019 (p = 0.02), respectively. From 2007 to 2020, overall PTBR and EPTBR were 5.68% and 0.255%, respectively. A significant difference in the PTBR and EPTBR existed between the eight Japanese regions. During this period, the number of pregnancies using assisted reproductive technology increased from 19 595 to 60 381, pregnant women became older, the employment rate of those of reproductive age increased, and nonregular employment was 54%, which was 2.5 times higher than for men. CONCLUSIONS: In Japan, after obstetrical guidelines were enacted in 2008, PTRBs decreased significantly even under the pressure of increasing preterm births. Countermeasures may be necessary for regions showing high PTBRs.

DOI： 10.1111/jog.15722

PubMed

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Xq chromosome duplication with complex rearrangements is generally acknowledged to be associated with neurodevelopmental disorders such as Pelizaeus-Merzbacher disease (PMD) and MECP2 duplication syndrome. For couples who required a PGT-M (pre-implantation genetic testing for monogenic disease) for these disorders, junction-specific PCR is useful to directly detect pathogenic variants. Therefore, pre-clinical workup for PGT-M requires the identification of the junction of duplicated segments in PMD and MECP2 duplication syndrome, which is generally difficult. METHODS: In this report, we used nanopore long-read sequencing targeting the X chromosome using an adaptive sampling method to identify breakpoint junctions in disease-causing triplications. RESULTS: By long-read sequencing, we successfully identified breakpoint junctions in one PMD case with PLP1 triplication and in another MECP2 triplication case in a single sequencing run. Surprisingly, the duplicated region involving MECP2 was inserted 45 Mb proximal to the original position. This inserted region was confirmed by FISH analysis. With the help of precise mapping of the pathogenic variant, we successfully re-established STR haplotyping for PGT-M and avoided any potential misinterpretation of the pathogenic allele due to recombination. CONCLUSION: Long-read sequencing with adaptive sampling in a PGT-M pre-clinical workup is a beneficial method for identifying junctions of chromosomal complex structural rearrangements. This article is protected by copyright. All rights reserved.

DOI： 10.1002/pd.6334

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Women who are undergoing preimplantation genetic testing for aneuploidy (PGT-A) often wish to know how many eggs will be required to optimize the chances of a live birth. However, no precise data on this can yet be provided during genetic counseling for this procedure. On the basis of PGT-A data from related studies and current databases, we have estimated that the number of zygotes required for a 50% chance of a live birth is 8 at age 40 but increases markedly to 21 at age 43. PGT-A markedly reduces the miscarriage rate per embryo transfer but does not alleviate the extremely high number of zygotes required for a live birth in women of an advanced maternal age. Detailed genetic counseling will therefore be desirable prior to undergoing this procedure.

DOI： 10.1080/19396368.2022.2151387

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Letrozole has been reported to be effective in treating anovulation, preventing ovarian hyperstimulation syndrome (OHSS), and retrieving oocytes in breast cancer patients. However, the role and mechanism of letrozole in follicular development remain unclear. RESULTS: We treated mouse preantral follicles with various treatments; we found no significant difference in follicle survival rates in the letrozole (LET) group compared with the control group, but the average diameter of follicles in the LET group tended to be larger (CTRL vs. LET 30, p = 0.064; CTRL vs. LET 100, p = 0.025). The estradiol concentrations in culture media of the LET group were significantly lower than those observed in the control group (CTRL vs. LET 30, p = 0.038; CTRL vs. LET 100, p = 0.025). We further found a marked increase in follicle-stimulating hormone receptor (FSHR) gene expression in response to letrozole treatment (CTRL vs. LET 30, p = 0.075; CTRL vs. LET 100, p = 0.034). This result suggested that increased FSHR expression promotes follicle development. Letrozole inhibited aromatase activity, but the effect was limited. Letrozole did not significantly reduce vascular endothelial growth factor (VEGF) gene expression. CONCLUSIONS: Letrozole may promote follicle development by increasing the expression of FSHR. Letrozole may be useful for fertility preservation of patients with estrogen-dependent cancers such as breast cancer and various other cancers. Whether letrozole has a direct effect in reducing OHSS requires further investigation.

DOI： 10.1186/s13048-022-01073-2

PubMed

researchmap

Language：English  

Maple syrup urine disease (MSUD) is a rare autosomal recessive inherited disorder of branched-chain amino acid metabolism caused by mutations in BCKDHA, BCKDHB, and DBT that encode the E1α, E1β, and E2 subunits of the branched-chain α-ketoacid dehydrogenase (BCKD) complex. Various MSUD-causing variants have been described; however, no structural rearrangements in BCKDHA have been reported to cause the classic MSUD phenotype. Here, we describe the classic patient with MSUD with compound heterozygous pathogenic variants in BCKDHA: a missense variant (NM_000709.3:c.757G > A, NP_000700.1:p.Ala253Thr) and a paracentric inversion disrupting Intron 1 of BCKDHA, which was identified by whole-genome sequencing and validated by fluorescence in situ hybridization. Using the sequence information of the breakpoint junction, we gained mechanistic insight into the development of this structural rearrangement. Furthermore, the establishment of junction-specific polymerase chain reaction could facilitate identification of the variant in case carrier or future prenatal/preimplantation tests are necessary.

DOI： 10.1002/jmd2.12333

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Structural analysis of small supernumerary marker chromosomes (sSMCs) has revealed that many have complex structures. Structural analysis of sSMCs by whole genome sequencing using short-read sequencers is challenging however because most present with a low level of mosaicism and consist of a small region of the involved chromosome. In this present study, we applied adaptive sampling using nanopore long-read sequencing technology to enrich the target region and thereby attempted to determine the structure of two sSMCs with complex structural rearrangements previously revealed by cytogenetic microarray. In adaptive sampling, simple specification of the target region in the FASTA file enables to identify whether or not the sequencing DNA is included in the target, thus promoting efficient long-read sequencing. To evaluate the target enrichment efficiency, we performed conventional pair-end short-read sequencing in parallel. Sequencing with adaptive sampling achieved a target enrichment at about a 11.0- to 11.5-fold higher coverage rate than conventional pair-end sequencing. This enabled us to quickly identify all breakpoint junctions and determine the exact sSMC structure as a ring chromosome. In addition to the microhomology and microinsertion at the junctions, we identified inverted repeat structure in both sSMCs, suggesting the common generation mechanism involving replication impairment. Adaptive sampling is thus an easy and beneficial method of determining the structures of complex chromosomal rearrangements.

DOI： 10.1038/s10038-021-01004-x

PubMed

researchmap

Language：English  

Ehlers-Danlos syndrome is a rare genetic disorder that presents with a variety of pathologies depending on the disease type. Among them, vascular Ehlers-Danlos syndrome requires extremely careful management as there have been many reports of fatal perinatal complications such as uterine rupture. Although hypermobile Ehlers-Danlos syndrome is less likely to cause fatal complications, symptoms such as arthralgia, hip dislocation, and depression may be seen throughout pregnancy. We report here a case of twin pregnancy in which Ehlers-Danlos syndrome was first suspected at 19 weeks of gestation. Vascular Ehlers-Danlos syndrome could not be ruled out based on family medical history, making it difficult to determine the perinatal management strategy. Prompt genetic testing did however rule out the vascular type and the patient was diagnosed with hypermobile Ehlers-Danlos syndrome from the clinical symptoms, enabling us to manage the pregnancy safely until 34 weeks of gestation.

DOI： 10.1016/j.crwh.2022.e00384

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Recently, radical vaginal hysterectomy (RVH) has developed into laparoscopically assisted radical vaginal hysterectomy (LARVH), which is associated with the laparoscopical procedure, and it is applied as radical vaginal trachelectomy and semi-radical vaginal hysterectomy. LARVH is indicated for patients with stage IB1 and IIA1 cervical carcinoma, especially those with a tumor size of less than 2 cm, because the cardinal ligaments cannot be resected widely. Although RVH that is associated with laparoscopic pelvic lymphadenectomy is the most used surgical procedure, radical trachelectomy may be performed either abdominally or vaginally (laparoscopic or robotic). One report found that the pregnancy rate was higher in patients who underwent minimally invasive or radical vaginal trachelectomy than in those who underwent radical abdominal trachelectomy.

DOI： 10.1055/s-0041-1739120

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Although many cervical cytology diagnostic support systems have been developed, it is challenging to classify overlapping cell clusters with a variety of patterns in the same way that humans do. In this study, we developed a fast and accurate system for the detection and classification of atypical cell clusters by using a two-step algorithm based on two different deep learning algorithms. METHODS: We created 919 cell images from liquid-based cervical cytological samples collected at Sapporo Medical University and annotated them based on the Bethesda system as a dataset for machine learning. Most of the images captured overlapping and crowded cells, and images were oversampled by digital processing. The detection system consists of two steps: (1) detection of atypical cells using You Only Look Once v4 (YOLOv4) and (2) classification of the detected cells using ResNeSt. A label smoothing algorithm was used for the dataset in the second classification step. This method annotates multiple correct classes from a single cell image with a smooth probability distribution. RESULTS: The first step, cell detection by YOLOv4, was able to detect all atypical cells above ASC-US without any observed false negatives. The detected cell images were then analyzed in the second step, cell classification by the ResNeSt algorithm, which exhibited average accuracy and F-measure values of 90.5% and 70.5%, respectively. The oversampling of the training image and label smoothing algorithm contributed to the improvement of the system's accuracy. CONCLUSION: This system combines two deep learning algorithms to enable accurate detection and classification of cell clusters based on the Bethesda system, which has been difficult to achieve in the past. We will conduct further research and development of this system as a platform for augmented reality microscopes for cytological diagnosis.

DOI： 10.1002/cam4.4460

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Intrauterine infection is one of the most important causes of maternal death. In perinatal emergency, we often miss an opportunity to obtain culture specimens. In this study, we tried to examine whether we investigated whether bacteria causing infection can be detected from a formalin-fixed paraffin-embedded (FFPE) placental specimen. We examined the placenta from a maternal invasive infection that resulted in infectious abortion at 18 weeks of gestation. The case was diagnosed by acute fever and abdominal pain, and the patient was cured after 3 weeks of intensive antimicrobial treatment. Four Streptococcus pyogenes strains were isolated from vaginal fluid and blood cultures of the patient. All of the strain types were emm1/ST28. We amplified the V1-V2 region of 16S rRNA from an FFPE placental specimen and sequencing was performed using a next-generation sequencer (NGS). Taxonomic analysis was then performed for sequenced data. We succeeded in detecting causative pathogens from the FFPE placenta: 69.1% of the predominantly identified bacteria were S. pyogenes and other small populations of bacteria were detected. Our results revealed the utility of NGS for 16S rRNA analysis of an FFPE placenta. This method may reveal previous perinatal invasive infections of unknown origin retrospectively.

DOI： 10.1007/s00795-021-00298-2

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wolters Kluwer Medknow Publications  

DOI： 10.4103/GMIT.GMIT_74_20

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

From 2000 to 2019, Japan's reproductive-age population gradually declined by 24%. In comparison, the Chlamydia trachomatis infection rate increased from 2016, with the syphilis infection rate increasing more sharply from 2014. Since 2013, the numbers of foreign tourists to Japan have also increased. From 2011 to 2018, the rate of increase in tourists was 5.02 times, while the rate of increase in syphilis patients was higher at 22.4 times. The lack of a one-to-one relationship between foreign tourists and syphilis cases suggests that cases of syphilis were transmitted to others. Although the prevalence of syphilis in the tourists' home countries (Korea in 2014 and China in 2013) was 20-30 times higher than that in Japan, the Japanese sex industry did not discriminate against foreign tourists, leading to increased STI infections in Japanese female sex workers. Indeed, from 2017 to 2018, a history of working in the sex industry for six months was identified as a risk factor for syphilis. The rise in Chlamydia trachomatis infections has lagged behind that of syphilis by two years, with the rate of increase lower. We suspect the difference in increasing rates of syphilis and chlamydial infections is due to the different methods of infection: syphilis can be transmitted by light physical contact, such as a kiss, whereas chlamydia requires close sexual contact, such as oral sex or sexual intercourse. Regardless, examinations and infection control are necessary to prevent the spread of STIs in Japan due to inbound tourists.

DOI： 10.1016/j.jiac.2021.05.015

PubMed

researchmap

Publisher：Research Square Platform LLC  

<title>Abstract</title>
Purpose

Radical trachelectomy (RT) with pelvic lymphadenectomy has become a new treatment option for young patients with uterine cervical cancer stages 1A2–1B1 who desire the preservation of their fertility. However, the application of RT for pregnant patients is still controversial. We comparatively studied both obstetrical and oncological outcomes of pregnant patients who underwent vaginal RT during pregnancy and those who underwent vaginal RT before pregnancy.
Methods

Both obstetrical and oncological results of eight patients who underwent vaginal RT with pelvic lymphadenectomy during pregnancy in our institute between 2010 and 2020 (Group A), and ten pregnant patients who underwent vaginal RT with pelvic lymphadenectomy before pregnancy during the same period (Group B) were reviewed based on their medical charts.
Results

There were no significant differences in blood loss, surgical time, or surgical completeness between Group A and Group B. Nor were there significant differences in obstetrical outcomes between the two groups. However, two of the eight patients in Group A had recurrence of the cancer. None of the patients in Group B has shown any signs of recurrence thus far.
Conclusion

Vaginal RT during pregnancy does not affect the obstetrical prognoses of patients with early invasive uterine cervical cancer, and it might be a tolerable treatment modality for them. However, oncologically, it should be performed carefully as there is a risk of recurrence.

Other Link： https://www.researchsquare.com/article/rs-228984/v1.html

DOI： 10.21203/rs.3.rs-228984/v1

researchmap

Language：English  

A 37-year-old pregnant woman who had undergone three previous cesarean sections was diagnosed as having placenta percreta. We decided to perform cesarean hysterectomy with bilateral common iliac artery balloon occlusion (CIABO). The duration of surgery was 2 h and 2 min and total estimated blood loss was 2600 mL. Surgery was completed without any surgical complications, but the pulse oximeter waveform of the left leg became undetectable during surgery. We immediately performed angiography after closure of laparotomy and found abnormal pooling of contrast media at the left common iliac artery in the region in which the balloon was positioned. We made a diagnosis of left common iliac artery dissection caused by CIABO. We performed emergent revascularization by intravascular stenting. We conclude that CIABO can cause common iliac artery dissection by mechanical stimulation of the inflated balloon. Careful intraoperative evaluation of limb ischemia and preparation of intravascular treatment is needed for a safe procedure.

DOI： 10.1111/jog.14601

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Mismatch repair protein deficiency (dMMR) is a favorable prognostic factor in colorectal cancer. It is also associated with aberrant expression of HLA class I molecules, which are required for cytotoxic T lymphocyte-mediated cancer immunotherapy. Because dMMR is frequently also found in endometrial cancers (ECs), we retrospectively investigated the expression of mismatch repair proteins and HLA class I molecules in 127 EC patients. In this study, EC patients being treated in our hospital were recruited from 2005 to 2009 and observed until December 2017. Lesion specimens were evaluated via immunohistochemistry for MSH6 and PMS2 (mismatch repair proteins) and HLA class I molecules. Expression of these molecules was statistically related to clinical and pathological factors and prognosis. dMMR was detected in 33 patients and did not correlate with the expression level of HLA class I molecules (P = 0.60). On the other hand, unexpectedly, multivariate analysis revealed that intact expression of HLA class I molecules was associated with p53 overexpression (P = 0.004). Neither dMMR nor decreased expression of HLA class I molecules were prognostic factors. These results are inconsistent with previous findings for colorectal cancer. A distinctive local tissue immune microenvironment would underlie the discrepancy in the results between EC and colorectal cancer.

DOI： 10.1007/s00795-020-00254-6

PubMed

researchmap

Language：English  

DOI： 10.1002/pd.5889

PubMed

researchmap

Language：Japanese   Publisher：(株)近代出版  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Endometrial cancer is a leading cause of cancer-associated mortality in women and has a poor prognosis in advanced stages. Our previous study revealed that BCL-2-associated athanogene 3 (BAG3) may contribute to enhancing cell viability through downregulation of microRNA (miR)-29b in endometrial cancer cell lines. In addition, a relationship between estrogen receptor α (ERα) and BAG3 was recently reported in several cancer cell types. The present study investigated the relationship between ERα and BAG3 in endometrial cancer cell lines. The results demonstrated that exogenous ERα overexpression enhanced BAG3 expression in the EMTOKA endometrial cancer cell line, which does not endogenously express ERα, but had no effect on BAG3 expression levels in the Ishikawa cell line, which does endogenously express ERα. In addition, ERα overexpression suppressed miR-29b expression and enhanced the expression of Mcl-1, a mediator situated downstream of BAG3, in EMTOKA cells, but not Ishikawa cells. ERα overexpression also enhanced EMTOKA, but not Ishikawa, endometrial cancer cell viability in the presence of cisplatin. These findings suggested that ERα may contribute to enhancing endometrial cancer cell resistance to anticancer agents through BAG3 overexpression.

DOI： 10.3892/ol.2020.12281

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本超音波医学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)メジカルビュー社  

Ichushi

researchmap

Language：Japanese   Publisher：日本遺伝カウンセリング学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：English  

DOI： 10.21037/atm-2020-78

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J04116&link_issn=&doc_id=20200817330032&doc_link_id=%2Fdy1jspnm%2F2020%2F005601%2F032%2F0198-0202%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdy1jspnm%2F2020%2F005601%2F032%2F0198-0202%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00535&link_issn=&doc_id=20200602180008&doc_link_id=10.18888%2Fsp.0000001268&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000001268&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Ichushi

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Radical tracheletomy (RT) with pelvic lymphadenectomy has become an option for young patients with early invasive uterine cervical cancer who desire to maintain their fertility. However, this operative method entails a high risk for the following pregnancy due to its radicality. METHODS: We have performed vaginal RT for 71 patients and have experienced 28 pregnancies in 21 patients. They were followed up carefully according to the follow-up methods we reported previously. Their pregnancy courses and prognoses after the pregnancy were retrospectively reviewed. RESULTS: All the vaginal RTs were performed safely without serious complications, including 6 patients who underwent the operation during pregnancy. The median time to be pregnant after RT was 29.5 months. 13 patients (46%) became pregnant without artificial insemination by husband or assisted reproductive technology. Cesarean section was performed for all of them. The median time of pregnancy was 34 weeks, and emergent cesarean section was performed for 7 pregnancies (25%). The median birth weight was 2156 g. Four patients had trouble with cervical cerclage, and they suffered from sudden premature preterm rupture of the membrane (pPROM) during the second trimester of pregnancy. We underwent transabdominal cerclage (TAC) for all of them and careful management for the prevention of uterine infection was performed. One patient had a recurrence of cancer during pregnancy. CONCLUSIONS: Both the obstetrical prognosis and oncological prognosis after vaginal RT have become favorable for pregnant patients after vaginal RT.

DOI： 10.1186/s12884-020-02949-1

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本感染症学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

Ichushi

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Hereditary antithrombin (AT) deficiency increases the risk of venous thromboembolism (VTE) in pregnant woman. We report the first case of administration of recombinant human antithrombin (rhAT) to a pregnant Japanese woman with AT deficiency. CASE REPORT: A 30-year-old woman, gravida 2 para 0, was referred to our hospital because of AT deficiency. Unfractionated heparin was administered from 13 weeks of gestation and rhAT was administered from labor onset. A cesarean section was performed and the patient and her baby were healthy, with no sequelae. CONCLUSION: We concluded that rhAT was effective for preventing VTE during delivery, with no potential infection risks.

DOI： 10.1016/j.tjog.2019.09.021

PubMed

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

AIM: Radical trachelectomy (RT) with pelvic lymphadenectomy has become an option for young patients with early invasive uterine cervical cancer who decide to maintain their fertility. However, this operative method entails a high risk for the following pregnancy due to its radicality. Therefore, RT for pregnant patients can be a challenge both for gynecologic oncologists and obstetricians. METHODS: We have performed vaginal RT for five pregnant patients with uterine cervical cancer stage 1B1 according to the method of Dargent et al. The operations were performed between 16 and 26 weeks of pregnancy, and the patients were followed up carefully according to the follow-up methods we reported previously. RESULTS: Vaginal RT was performed for five patients without any troubles. Four of the patients continued their pregnancies until almost 34 weeks or longer under our previously published follow-up schedule. The pregnancy of one patient was terminated at 26 weeks due to recurrence of the cancer. CONCLUSION: Expansion of vaginal RT for pregnant patients with uterine cervical cancer could be a practical option for pregnant patients with early invasive uterine cervical cancer.

DOI： 10.1111/jog.13964

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Uterine endometrial carcinoma is one of the common cancers in females. Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are a small subpopulation of cancer cells that are tumorigenic and are resistant to treatments, thus they are focused as treatment targets. However, the heterogeneity of CSCs/CICs is still elusive, and we therefore analyzed CSCs/CICs at the clonal level. We previously established sphere-cultured CSCs/CICs from primary human uterine endometrial carcinoma, and we isolated several clones from CSCs/CICs in this study. Interestingly, we established two types of clones based on the growth pattern. The clones were termed sphere clones (S clones) and leukemia-like clones (LL clones). Functional analysis revealed that S clones are resistant to chemotherapy, whereas LL clones are sensitive to chemotherapy. On the other hand, S clones are less tumorigenic, while LL clones are highly tumorigenic. Transcriptome analysis using serial analysis of gene expression sequencing (SAGE-Seq) revealed distinctive gene expression profiles in S clone cells and LL clone cells. The results indicate that CSCs/CICs are composed of functionally heterogenic subpopulations including highly tumorigenic clones and treatment-resistant clones and that the characteristics of CSCs/CICs might be determined by the characteristics of different clones that compose CSCs/CICs.

DOI： 10.1016/j.yexmp.2018.11.013

PubMed

researchmap

Language：English  

A cesarean scar can cause abnormal uterine bleeding including prolonged menstruation or postmenstrual spotting. Our patient showed massive uterine bleeding from a cesarean scar and needed blood transfusion for hemorrhagic shock. A cesarean section had only been performed once for delivery stop 9 years ago. Recurrent hemorrhage could not be controlled by conservative treatment, and we performed laparoscopic scar resection and repair. The abnormal uterine bleeding was successfully stopped, and the menstrual cycle was normalized after surgical treatment. We should be aware that even an uneventful cesarean section may have a risk of massive hemorrhage postoperatively as in the present case.

DOI： 10.4103/GMIT.GMIT_69_18

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Umbilical cord entanglement is known to be a major cause of fetal hypoxia and to be correlated with several neonatal complications, but almost all of the previous reports were restricted to nuchal cord. In this study, we retrospectively examined the correlation between multiple part cord entanglement and pregnancy outcomes. MATERIALS AND METHODS: A total of 2156 cases were recruited from term deliveries in our hospital from 2008 to 2012. We counted umbilical cord loop numbers not only for nuchal cord but also for trunk and limb cord entanglement. We classified the cases into three groups: no loop, single loop and multiple loops group. We statistically analyzed pregnancy outcomes statistically in the three groups. RESULTS: One thousand, four hundred and fifty-eight cases had no cord entanglement, 594 cases had single loop entanglement and 104 cases had multiple loops entanglement. Values of umbilical artery blood, pH (p = 0.002) and base excess (p < 0.001) showed significantly unfavorable status in entanglement cases, especially in the multiple loops group. A significantly larger percentage of neonates in the multiple loops group needed for oxygen (p < 0.001). CONCLUSION: Multiple umbilical cord entanglement is highly correlated with early neonatal unfavorable status and need for resuscitation.

DOI： 10.1016/j.tjog.2018.09.001

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Single cell transcriptome analysis of a cancer tissue can provide objective assessment of subtype population or the activation of each of various microenvironment component cells. In this study, we applied our newly developed technique of single cell analysis to the myometrial infiltration side (M-side) and the endometrial side (E-side) of a human endometrioid adenocarcinoma with squamous differentiation tissues. We also analyzed spherogenic cultures derived from the same tissue to identify putative regulators of stemness in vivo. Cancer cells in the E-side were highly malignant compared with those in the M-side. Many cells on the E-side were positive for spheroid-specific tumorigenesis-related markers including SOX2. In addition, there were higher numbers of epithelial-to-mesenchymal transition (EMT) cells in the E-side compared with the M-side. This study identified a site containing cells with high malignant potential such as EMT and cancer stem-like cells in cancer tissues. Finally, we demonstrate that established endometrioid adenocarcinoma subtype classifiers were variably expressed across individual cells within a tumor. Thus, such intratumoral heterogeneity may be related to prognostic implications.

DOI： 10.1038/s41598-017-14676-3

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cancer stem-like cells (CSCs)/ cancer-initiating cells (CICs) are defined by their higher tumor-initiating ability, self-renewal capacity and differentiation capacity. CSCs/CICs are resistant to several therapies including chemotherapy and radiotherapy. CSCs/CICs thus are thought to be responsible for recurrence and distant metastasis, and elucidation of the molecular mechanisms of CSCs/CICs are essential to design CSC/CIC-targeting therapy. In this study, we analyzed the molecular aspects of gynecological CSCs/CICs. Gynecological CSCs/CICs were isolated as ALDH1high cell by Aldefluor assay. The gene expression profile of CSCs/CICs revealed that several genes related to stress responses are preferentially expressed in gynecological CSCs/CICs. Among the stress response genes, a small heat shock protein HSP27 has a role in the maintenance of gynecological CSCs/CICs. The upstream transcription factor of HSP27, heat shock factior-1 (HSF1) was activated by phosphorylation at serine 326 residue (pSer326) in CSCs/CICs, and phosphorylation at serine 326 residue is essential for induction of HSP27. Immunohistochemical staining using clinical ovarian cancer samples revealed that higher expressions of HSF1 pSer326 was related to poorer prognosis. These findings indicate that activation of HSF1 at Ser326 residue and transcription of HSP27 is related to the maintenance of gynecological CSCs/CICs.

DOI： 10.18632/oncotarget.16361

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Lung cancer is one of the most common malignancies with a high rate of mortality. Lung cancer stem-like cells (CSCs)/ cancer-initiating cells (CICs) play major role in resistance to treatments, recurrence and distant metastasis and eradication of CSCs/CICs is crucial to improve recent therapy. Cytotoxic T lymphocytes (CTLs) are major effectors of cancer immunotherapy, and CTLs recognize antigenic peptides derived from antigens that are presented by major histocompatibility complex (MHC) class I molecules. In this study, we analyzed the potency of a cancer-testis (CT) antigen, brother of the regulator of the imprinted site variant subfamily 6 (BORIS sf6), in lung CSC/CIC immunotherapy. BORIS sf6 mRNA was expressed in lung carcinoma cells (9/19), especially in sphere-cultured lung cancer stem-like cells, and in primary lung carcinoma tissues (4/9) by RT-PCR. Immunohistochemical staining using BORIS sf6-specific antibody revealed that high expression of BORIS sf6 is related to poorer prognosis. CTLs could be induced by using a human leukocyte antigen, (HLA)-A2 restricted antigenic peptide (BORIS C34_24(9)), from all of 3 HLA-A2-positive individuals, and CTL clone cells specific for BORIS C34_24(9) peptide could recognize BORIS sf6-positive, HLA-A2-positive lung carcinoma cells. These results indicate that BORIS sf6 is a novel target of lung cancer immunotherapy that might be useful for targeting treatment-resistant lung cancer stem-like cells.

DOI： 10.1371/journal.pone.0171460

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

AIM: Cervical intra-epithelial neoplasia (CIN) is the precancerous stage of cervical cancer. Standard treatment for high-grade CIN is conization of the cervix. The risk of preterm birth following conization has been discussed recently. In contrast, laser vaporization is believed not to affect perinatal outcome, but the long-term effectiveness of each surgical procedure is still unclear. The aim of this prospective unmatched-cohort study was therefore to compare virological and cytological clearance and recurrence risk between conization and vaporization for CIN3. METHODS: Subject consisted of CIN3 patients treated at the present hospital between 2007 to 2011 and followed up until December 2014. One hundred and one patients were treated with laser conization, and 137 with vaporization. The surgical procedure was selected on the basis of colposcopy, pathological grade and patient's hope for pregnancy. RESULTS: There were no significant differences in cure rate, human papilloma virus (HPV) clearance rate or recurrence rates between the conization and vaporization groups. Risk ratio of recurrence for each surgical procedure adjusted for age and HPV persistence status were analyzed on Cox proportional hazards modeling. Recurrence risk ratio for patients treated by vaporization was 6.21 (95%CI: 0.65-59.19; P = 0.111) compared with conization and there were no significant differences. No adverse pregnancy outcome was observed in the vaporization group compared with conization. CONCLUSIONS: Laser vaporization is useful for young patients with CIN3 who hope for pregnancy in the future.

DOI： 10.1111/jog.13113

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Cancer-initiating cells (CICs) are thought to be essential for tumor maintenance, recurrence, and distant metastasis, and they are therefore reasonable targets for cancer therapy. Cancer immunotherapy is a novel approach to target cancer. In this study, we aimed to establish novel CIC-targeting immunotherapy. EXPERIMENTAL DESIGN: Colorectal cancer (CRC) CICs were isolated as side population (SP) cells. The gene expression profile of CRC CICs was analyzed by cDNA microarray and RT-PCR. Protein expression of olfactory receptor family 7 subfamily C member 1 (OR7C1) were analyzed by Western blot and immunohistochemical staining. The functions of OR7C1 were analyzed by gene overexpression and gene knockdown using siRNAs. OR7C1-positive cells were isolated by a flow cytometer and analyzed. CTLs specific for OR7C1 peptide were generated, and the antitumor effect was addressed by mice adoptive transfer model. RESULTS: OR7C1 has essential roles in the maintenance of colon CICs, and the OR7C1-positive population showed higher tumorigenicity than that of the OR7C1-negative population, indicating that OR7C1 is a novel functional marker for colon CIC. Immunohistochemical staining revealed that OR7C1 high expression was correlated with poorer prognosis in CRC patients. OR7C1-derived antigenic peptide-specific CTLs showed specific cytotoxicity for CICs, and an OR7C1-specific CTL clone showed a greater antitumor effect than did a CTL clone targeting all cancer cells in a CTL adoptive transfer mouse model. CONCLUSIONS: OR7C1 is a novel marker for colon CICs and can be a target of potent CIC-targeting immunotherapy. Clin Cancer Res; 22(13); 3298-309. ©2016 AACR.

DOI： 10.1158/1078-0432.CCR-15-1709

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Epithelial ovarian cancer (EOC) is one of the most lethal cancers in females. Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) have been reported to be origin of primary and recurrent cancers and to be resistant to several treatments. In this study, we identified matrix metalloproteinase-10 (MMP10) is expressed in CSCs/CICs of EOC. An immunohistochemical study revealed that a high expression level of MMP10 is a marker for poor prognosis and platinum resistance in multivariate analysis. MMP10 gene overexpression experiments and MMP10 gene knockdown experiments using siRNAs revealed that MMP10 has a role in the maintenance of CSCs/CICs in EOC and resistance to platinum reagent. Furthermore, MMP10 activate canonical Wnt signaling by inhibiting noncanonical Wnt signaling ligand Wnt5a. Therefore, MMP10 is a novel marker for CSCs/CICs in EOC and that targeting MMP10 is a novel promising approach for chemotherapy-resistant CSCs/CICs in EOC.

DOI： 10.18632/oncotarget.8645

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cervical cancer is a major cause of cancer death in females worldwide. Cervical cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are resistant to conventional radiotherapy and chemotherapy, and CSCs/CICs are thought to be responsible for recurrence. Eradication of CSCs/CICs is thus essential to cure cervical cancer. In this study, we isolated cervical CSCs/CICs by sphere culture, and we identified a cancer testis (CT) antigen, CTCFL/BORIS, that is expressed in cervical CSCs/CICs. BORIS has 23 mRNA isoform variants classified by 6 subfamilies (sfs), and they encode 17 different BORIS peptides. BORIS sf1 and sf4 are expressed in both CSCs/CICs and non-CSCs/CICs, whereas BORIS sf6 is expressed only in CSCs/CICs. Overexpression of BORIS sf6 in cervical cancer cells increased sphere formation and tumor-initiating ability compared with those in control cells, whereas overexpression of BORIS sf1 and BORIS sf4 resulted in only slight increases. Thus, BORIS sf6 is a cervical CSC/CIC-specific subfamily and has a role in the maintenance of cervical CSCs/CICs. BORIS sf6 contains a specific c-terminal domain (C34), and we identified a human leukocyte antigen (HLA)-A2-restricted antigenic peptide, BORIS C34_24(9) encoded by BORIS sf6. A BORIS C34_24(9)-specific cytotoxic T cell (CTL) clone showed cytotoxicity for BORIS sf6-overexpressing cervical cancer cells. Furthermore, the CTL clone significantly suppressed sphere formation of CaSki cells. Taken together, the results indicate that the CT antigen BORIS sf6 is specifically expressed in cervical CSCs/CICs, that BORIS sf6 has a role in the maintenance of CSCs/CICs, and that BORIS C34_24(9) peptide is a promising candidate for cervical CSC/CIC-targeting immunotherapy.

DOI： 10.18632/oncotarget.7165

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cytotoxic T lymphocytes (CTLs) recognize the human leukocyte antigen (HLA) class I and antigenic peptide complex, and they play a crucial role in cancer immunity. Our recent study revealed that HLA class I downregulation is related to poorer prognosis and a low level of intratumoral CTLs is associated with platinum resistance, indicating the significance of immunological surveillance.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1080/2162402X.2015.1005507

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Epithelial ovarian cancer (EOC) is one of the most deadly carcinomas in females. Immune systems can recognize EOCs; however, a defect of human leukocyte antigen (HLA) class I expression is known to be a major mechanism for escape from immune systems, resulting in poor prognosis. The purpose of this study is to identify novel correlations between immunologic responses and other clinical factors. We investigated the expression of immunologic components in 122 cases of EOCs for which surgical operations were performed between 2001 and 2011. We immunohistochemically stained EOC specimens using an anti-pan HLA class I monoclonal antibody (EMR8-5) and anti-CD3, -CD4, and -CD8 antibodies, and we analyzed correlations between immunologic parameters and clinical factors. In multivariate analysis that used the Cox proportional hazards model, independent prognostic factors for overall survival in advanced EOCs included low expression level of HLA class I [risk ratio (RR), 1.97; 95% confidence interval (CI), 1.01-3.83; P = 0.046] and loss of intraepithelial cytotoxic T lymphocyte (CTL) infiltration (RR, 2.11; 95% CI, 1.06-4.20; P = 0.033). Interestingly, almost all platinum-resistant cases showed a significantly low rate of intraepithelial CTL infiltration in the χ(2) test (positive vs. negative: 9.0% vs. 97.7%; P < 0.001). Results from a logistic regression model revealed that low CTL infiltration rate was an independent factor of platinum resistance in multivariate analysis (OR, 3.77; 95% CI, 1.08-13.12; P = 0.037). Platinum-resistant EOCs show poor immunologic responses. The immune escape system of EOCs may be one of the mechanisms of platinum resistance.

DOI： 10.1158/2326-6066.CIR-14-0101

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small population of cells within cancer that contribute to cancer initiation and progression. Cancer-associated fibroblasts (CAFs) are stromal fibroblasts surrounding tumor cells, and they have important roles in tumor growth and tumor progression. It has been suggested that stromal fibroblasts and CSCs/CICs might mutually cooperate to enhance their growth and tumorigenic capacity. In this study, we investigated the effects of fibroblasts on tumor-initiating capacity and stem-like properties of ovarian CSCs/CICs. CSCs/CICs were isolated from the ovarian carcinoma cell line HTBoA as aldehyde dehydrogenase 1 high (ALDH1(high)) population by the ALDEFLUOR assay. Histological examination of tumor tissues derived from ALDH1(high) cells revealed few fibrous stroma, whereas those derived from fibroblast-mixed ALDH1(high) cells showed abundant fibrous stroma formation. In vivo tumor-initiating capacity and in vitro sphere-forming capacity of ALDH1(high) cells were enhanced in the presence of fibroblasts. Gene expression analysis revealed that fibroblast-mixed ALDH1(high) cells had enhanced expression of fibroblast growth factor 4 (FGF4) as well as stemness-associated genes such as SOX2 and POU5F1. Sphere-forming capacity of ALDH1(high) cells was suppressed by small-interfering RNA (siRNA)-mediated knockdown of FGFR2, the receptor for FGF4 which was expressed preferentially in ALDH1(high) cells. Taken together, the results indicate that interaction of fibroblasts with ovarian CSCs/CICs enhanced tumor-initiating capacity and stem-like properties through autocrine and paracrine FGF4-FGFR2 signaling.

DOI： 10.1038/labinvest.2014.122

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Ovarian cancer is the leading cause of death from gynecologic cancer, reflecting its often late diagnosis and its chemoresistance. We identified a set of microRNAs whose expression is altered upon BAG3 knockdown. Our primary objective was to examine the relationships between BAG3, miR-29b and Mcl-1, an antiapoptotic Bcl-2 family protein, in ovarian cancer cells. METHODS: Ovarian cancer cells were cultured and their responsiveness to paclitaxel was tested. Microarray analysis was performed to identify microRNAs differentially expressed in ES2 BAG3 knockdown ovarian cancer cells and their control cells. Primary ovarian cancer tissues were obtained from 56 patients operated on for ovarian cancer. The patients' clinical and pathological data were obtained from their medical records. RESULTS: BAG3 knockdown increased the chemosensitivity to paclitaxel of ES2 ovarian clear cell carcinoma cells to a greater degree than AMOC2 serous adenocarcinoma cells. qRT-PCR analysis showed that miR-29b expression was significantly upregulated in primary cancer tissue expressing low levels of BAG3, as compared to tissue expressing high levels. Moreover, levels of miR-29b correlated significantly with progression-free survival. Upregulation of miR-29b also reduced levels of Mcl-1 and sensitized ES2 cells to low-dose paclitaxel. CONCLUSIONS: BAG3 knockdown appears to downregulate expression of Mcl-1 through upregulation of miR-29b, thereby increasing the chemosensitivity of ovarian clear cell carcinoma cells. This suggests that BAG3 is a key determinant of the responsiveness of ovarian cancer cells, especially clear cell carcinoma, to paclitaxel and that BAG3 may be a useful therapeutic target for the treatment of ovarian cancer.

DOI： 10.1016/j.ygyno.2014.06.024

PubMed

researchmap

Language：Japanese   Publisher：The Japanese Society of Clinical Cytology  

<b><i>Objective</i></b> : To examine the clinical implications of atypical squamous cells of undetermined significance (ASC-US) in cytology of the uterine cervix.<br><b><i>Study Design</i></b> : We examined the cases of ASC-US diagnosed in our hospital : a total of 12141 women who participated in the screening for cancer of the cervix between January 2010 and December 2011 were included in our study.<br><b><i>Results</i></b> : Of the patients, 1.9% were found to have ASC-US, and 66% of these cases had evidence of infection with high-risk HPV. After one-year follow-up, CIN 1/2 was confirmed in 25/21% of the cases. In 14 of the 19 cases of CIN 1, atypical cytological features could not be detected at the follow-up. We treated 10 cases of CIN 2/3 and followed up 6 cases. Multivariate modeling identified only one factor affecting the risk of CIN, that is high-risk HPV infection.<br><b><i>Conclusion</i></b> : The results of the multivariate analysis identified high-risk HPV infection in cases of ASC-US as an independent risk factor for CIN.

Other Link： http://search.jamas.or.jp/link/ui/2015067989

DOI： 10.5795/jjscc.53.362

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small population of cancer cells that have high tumorigenicity. Furthermore, CSCs/CICs are resistant to several cancer therapies, and CSCs/CICs are therefore thought to be responsible for cancer recurrence after treatment and distant metastasis. In epithelial ovarian cancer (EOC) cases, disease recurrence after chemotherapy is frequently observed, suggesting ovarian CSCs/CICs are involved. There are four major histological subtypes in EOC, and serous adenocarcinoma and clear cell adenocarcinoma are high-grade malignancies. We therefore analyzed ovarian CSCs/CICs from ovarian carcinoma cell lines (serous adenocarcinoma and clear cell adenocarcinoma) and primary ovarian cancer cells in this study. We isolated ovarian CSCs/CICs as an aldehyde dehydrogenase 1 high (ALDH1(high)) population from 6 EOC cell lines (3 serous adenocarcinomas and 3 clear cell adenocarcinomas) by the ALDEFLUOR assay. ALDH1(high) cells showed greater sphere-forming ability, higher tumorigenicity and greater invasive capability, indicating that ovarian CSCs/CICs are enriched in ALDH1(high) cells. ALDH1(high) cells could also be isolated from 8 of 11 primary ovarian carcinoma samples. Immunohistochemical staining revealed that higher ALDH1 expression levels in ovary cancer cases are related to poorer prognosis in both serous adenocarcinoma cases and clear cell adenocarcinoma cases. Taken together, the results indicate that ALDH1 is a marker for ovarian CSCs/CICs and that the expression level of ALDH1 might be a novel biomarker for prediction of poor prognosis.

DOI： 10.1371/journal.pone.0065158

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

A diagnosis of cervical cancer during pregnancy poses difficult management and ethical problems. Survival of the patient is the foremost concern, but fetal viability and well-being must also be addressed. Radical trachelectomy (RT) has recently begun to be performed as a possible treatment modality for early stage invasive uterine cervical cancer in pregnant patients who would like to continue their pregnancy. A 32-year-old Japanese woman visited a local hospital for prenatal care, and was diagnosed with a FIGO I B1 adenocarcinoma of the uterine cervix. She had a strong desire to avoid pregnancy termination, so she was admitted to our hospital for fertility-preserving surgery. After extensive counseling, vaginal radical trachelectomy with abdominal pelvic lymphadenectomy was performed in the 16th gestational week. The excised uterine cervix and lymph nodes were pathologically negative for cancer. To maintain her pregnancy, daily vaginal disinfection with povidone iodine, bed rest, and administration of ritodrine and an ulinastatin vaginal suppository were continued until the delivery. At 34 weeks' gestation, an emergency cesarean section was performed because of sudden premature rupture of the membranes. A baby girl was born weighing 2112 g, with Apgar score of 8/9. The mother remains without evidence of recurrence at the time of this report. This is the first case of successful pregnancy and delivery in Japan after vaginal RT.

DOI： 10.1007/s10147-011-0209-3

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本性感染症学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)診断と治療社  

Other Link:： https://search.jamas.or.jp/default/link?pub_year=2024&ichushi_jid=J00642&link_issn=&doc_id=20241023100021&doc_link_id=10.34433%2Fpp.0000001351&url=https%3A%2F%2Fdoi.org%2F10.34433%2Fpp.0000001351&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産婦人科感染症学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本内分泌学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本産婦人科感染症学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本遺伝カウンセリング学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本内分泌学会  

Ichushi

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本性感染症学会  

Ichushi

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本性感染症学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本医療情報学会  

Ichushi

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Other Link:： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J04116&link_issn=&doc_id=20230524470018&doc_link_id=%2Fdy1jspnm%2F2023%2F005901%2F018%2F0111-0115%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdy1jspnm%2F2023%2F005901%2F018%2F0111-0115%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：Japan Society of Perinatal and Neonatal Medicine  

DOI： 10.34456/jjspnm.59.1_111

CiNii Research

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本臨床微生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本臨床微生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)メジカルビュー社  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)メジカルビュー社  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本感染症学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)東京医学社  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本医療情報学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(株)メジカルビュー社  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本遺伝カウンセリング学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本遺伝カウンセリング学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本超音波医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本感染症学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)診断と治療社  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：北海道臨床細胞学会  

Ichushi

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：(福)北海道社会事業協会帯広病院  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)診断と治療社  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本周産期・新生児医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産婦人科感染症学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本超音波医学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

researchmap

Language：Japanese   Publisher：(福)北海道社会事業協会帯広病院  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本感染症学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：English  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=456306

researchmap

Language：English  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=456057

researchmap

Language：English   Publishing type：Research paper, summary (international conference)  

Web of Science

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：東北連合産科婦人科学会・北日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：English  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=455425

researchmap

Language：English   Publishing type：Research paper, summary (international conference)  

Web of Science

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese  

Other Link:： http://search.jamas.or.jp/link/ui/2014229553

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：金原出版(株)  

Ichushi

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本産科婦人科内視鏡学会  

Other Link:： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2013&ichushi_jid=J02563&link_issn=&doc_id=20140121600018&doc_link_id=%2Fcj7sanai%2F2013%2F002901%2F018%2F0158-0162%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcj7sanai%2F2013%2F002901%2F018%2F0158-0162%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本婦人科腫瘍学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)診断と治療社  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本産科婦人科学会  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=449986

researchmap

Language：English  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=451399

researchmap

Language：Japanese   Publisher：日本産科婦人科学会  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=450137

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)診断と治療社  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：北海道産科婦人科学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本産科婦人科学会  

Other Link:： https://projects.repo.nii.ac.jp/?action=repository_uri&item_id=448616

CiNii Research

researchmap